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Survivin was recently described as an apoptosis inhibitor. Its pathogenic role in gastric cancer is largely unknown. Expression of
survivin in gastric cancer and non-cancer ﬁrst-degree relatives, and its association with apoptosis and cyclo-oxygenase-2
expression was investigated. Fifty gastric cancer, 30 non-cancer ﬁrst-degree relatives, 20 normal controls and ﬁve gastric cancer
cell lines were studied. Survivin and cyclo-oxygenase-2 were evaluated by reverse transcriptase-polymerase chain reaction,
immunohistochemistry and Western blot. Survivin expression was absent from normal gastric mucosa. All ﬁve cancer cell lines
and 34 out of 50 (68%) human gastric cancer tissues expressed survivin mRNA. Survivin expression was less frequent (22%;
P50.001) in adjacent non-tumour gastric tissues. Immunohistochemistry and Western blot obtained similar ﬁndings. Gastric
cancers with survivin expression displayed signiﬁcantly reduced apoptosis (P=0.02), and associated with cyclo-oxygenase-2
overexpression at both mRNA (P=0.001) and protein levels (P=0.041). Moreover, survivin mRNA was detected in the gastric
mucosa of eight (27%) non-cancer relatives. Expression in non-cancer patients showed positive correlation with H. pylori
infection (P=0.004). This demonstrates the frequent expression of survivin in gastric cancer and in ﬁrst-degree relatives. Co-
expression of survivin and cyclo-oxygenase-2 may suggest multiple pathways contributing to the inhibition of apoptosis in
gastric cancer.
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Regulation of apoptosis, or programmed cell death, is crucial to
the preservation of homeostasis and morphogenesis of human
tissue (Vaux et al, 1994). Disturbance of this process by aber-
rantly extending cell viability or favouring accumulation of
transforming mutation is thought to contribute to carcinogenesis
(Thompson, 1995). IAP (inhibitior of apoptosis) protein family
directly inhibits caspase and pro-caspase molecules that function
as potential modulators of the terminal effect phase of cell death
and survival (Deveraux et al, 1997; Roy et al, 1997; LaCasse et
al, 1998). Survivin, a new member of the IAP family, was
recently identiﬁed to be a novel antiapoptotic gene (Ambrosini
et al, 1997; Adida et al, 1998; Tamm et al, 1998). It inhibits
apoptosis by binding speciﬁcally to the terminal effected cell
death proteases, caspase-3 and -7 in vitro, thereby inhibiting
caspase activity and apoptosis in cells exposed to diverse apopto-
tic stimuli (Tamm et al, 1998). Survivin expression was reported
in several apoptosis related foetal tissues, including lung, liver,
heart, and gastrointestinal tract (Adida et al, 1998), but not in
differentiated tissues except for placenta and thymus (Ambrosini
et al, 1997). Several reports have noticed elevated levels of survi-
vin in tumour tissues when compared to normal tissue
(Ambrosini et al, 1997; Adida et al, 1998; Tamm et al, 1998).
The role of survivin in gastric carcinogenesis is, however, largely
unknown.
Increased cyclo-oxygenase-2 (COX-2) expression has been
demonstrated in the process of gastric carcinogenesis (Ristimaki
et al, 1997; Sung et al, 2000; Leung et al, 2001). Considerable
evidence suggests that the increase in tumorigenic potential of
COX-2 expressing cells is related to the resistance to apoptosis
(Tsujii and DuBois, 1995). Although the mechanism underlying
COX-2-mediated inhibition of apoptosis is largely unknown,
previous studies revealed that COX-2 overexpression in intestinal
epithelial cells increased level of IAP (Tsujii and DuBois, 1995).
Furthermore, prostaglandin E2, the major product of COX-2, has
been shown to increase bcl-2 expression, another suppressor of
apoptosis, in human colon cancer cells (Sheng et al, 1998). In
contrast, treatment with selective COX-2 inhibitors down-regulates
Bcl-2 expression and induces apoptosis (Tsujii and DuBois, 1995).
All of these ﬁndings indicate that COX-2 is involved in the inhibi-
tion of apoptosis signalling by interaction with IAP. In contrast to
bcl-2, survivin is unique in that it is undetectable in normal adult
tissues, but abundantly expressed in transformed cells and a variety
of human cancers. Little, however, is known the interaction
between COX-2 and survivin.
In the present study, we sought to examine survivin expression
in gastric cancer and in ﬁrst degree-relatives of gastric cancer
patients in order to elucidate the role of survivin in the process
of gastric carcinogenesis. In addition, we studied the correlation
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non-cancerous gastric tissues.
MATERIALS AND METHODS
Cancer cell line
The human gastric cancer cell lines KATO III, MKN45, MKN28,
AGS and N87 were obtained from Riken Cell Bank (Tsukuba,
Japan) and American Type Culture Collection (Rockville, MD,
USA). All cell lines, with the exception of Kato III, were main-
tained in RPMI 1640 medium (Gibco BRL, Gaithersburg, MD,
USA) supplemented with 10% foetal bovine serum (Gibco BRL).
Kato III was cultured in 80% RPMI 1640 medium and 20% foetal
bovine serum.
Gastric tissue samples
Fifty patients undergoing surgery for primary gastric cancer were
examined. There were 33 males and 17 females with a mean age
of 62.2 years (range from 36–83). Paired gastric tumours and
adjacent normal gastric mucosa were obtained from each patient
at the time of surgery. The samples were immediately frozen in
liquid nitrogen and were stored at 7808C. The remaining tissue
specimens were ﬁxed in 10% formalin and embedded in parafﬁn
for routine histological examination and immunohistochemical
analysis. Tumours were reviewed and classiﬁed into intestinal or
diffuse types according to Lauren, and the disease was staged
according to the UICC/AJCC TNM classiﬁcation (Sobin and
Wittekind, 1997). In addition, 30 ﬁrst-degree relatives of gastric
cancer patients and 20 normal control subjects without a family
history of gastric cancer were examined. Gastric biopsy specimens
were obtained from the gastric antrum and corpus of these
patients. Tissues were processed as mentioned above. The severity
of gastritis and H. pylori colonization of the non-tumorous gastric
mucosa was classiﬁed according to the updated Sydney system
(Dixon et al, 1996). H. pylori infection was documented by histol-
ogy and rapid urease test. This study was approved by the Ethics
Committee of Medical Faculty of the Otto-von-Guericke Univer-
sity, Magdeburg and informed consent had been obtained from
each subjects.
RT–PCR and sequencing
Gastric tissue specimens were homogenized with an ultrasound
homogenizer. Total RNA was extracted by using RNA Tri Reagents
(CINNA/MRC, Cincinnati, Ohio, USA) according to the manufac-
turer’s protocol. One-mg of total RNA was reverse transcribed into
cDNA by using dNTPs (1 mM), 5X reverse transcription buffer
(500 mM Tris-HCl pH 8.3, 250 mM KCl, 50 mM MgCl2 and
50 mM DTT), 16 units RNasin, and 2.5 units of AMV reverse tran-
scriptase (Gibco BRL, Life Technologies).
For PCR, the primer sequences and expected product sizes
were as follows: survivin, (forward) 5'-GGACCACCGCATCTC-
TACAT-3' and (reverse) 5'-GCACTTTCTTCGCAGTTTCC-3',
338 base pairs (bp); COX-2, (forward) 5'-AGATCATCTCT-
GCCTGAGTATCTT 3', (reverse) 5'-TTCAAATGAGATTGTGG-
GAAAAT-3', 305 bp; and b-actin, (forward) 5'-TGACGGGG-
TCACCCACACTGTGCCCATCTA-3', (reverse) 5'-CTAGAAGCA-
TTTGCGGTGGACGATGGAGGG-3', 654 bp. The reaction was
performed at 958C for 1.5 min, and followed by 35 cycles of
denaturating at 958C for 24 s, annealing at 588C for 48 s and
extension at 728C for 1 min. The PCR products were separated
on 1.5% agarose gel and saved as digital images (Uvigrab;
UVItec, Cambridge, UK) (Figure 1). The sequences of the
PCR products were conﬁrmed by automated sequencing (ABI
Prism 310 Genetic Analyzer; Perkin Elmer, Branchburg, NJ,
USA).
Immunohistochemical staining for survivin and COX-2
Expression of survivin and COX-2 protein was examined by
avidin-biotin complex (ABC) immunoperoxidase method. Depar-
afﬁnized sections were treated with 3% hydrogen peroxide to
block endogenous peroxidase activity. After blocking with 5%
normal serum for 20 min, the primary antibody was applied
and incubated overnight at 48C for survivin (1:200 dilution;
#500-201, Novus Biologicals, Littleton, CO, USA) and at room
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Figure 1 (A) Expression of survivin and COX-2 mRNA in gastric cancer cell lines (lane 1: NCI-N87; lane 2: MKN45), gastric cancer tissues (T) and paired
non-tumour tissues (NT) (lanes 3–6), corpus (C) and antrum (A) biopsies of ﬁrst-degree relatives (lanes 7–8) and non-cancer control (lanes 9–10). The
338 bp human survivin-speciﬁc sequence, 305 bp human COX-2-speciﬁc sequence and a 654 bp b-actin sequence were ampliﬁed from cDNA of gastric
cancer cell lines and gastric tissues, separated by agarose gel electrophoresis and visualised by ethidium bromide staining. (B) Densitometry of survivin and
COX-2 transcripts, standardised to b-actin, for the conditions listed above in A.
Survivin and COX-2 expression in gastric cancer
JY uet al
92
British Journal of Cancer (2002) 87(1), 91–97 ã 2002 Cancer Research UKtemperature for 2 h for COX-2 (1:100 dilution; #SC-1745, Santa
Cruz Biotechnology, Santa Cruz, CA, USA) respectively. After
rinsing, the biotinylated secondary antibody and ABComplex/
HRP (Dako A/S, Denmark) were applied. Peroxidase activity
was visualized by applying the diaminobenzidine chromogen.
The sections were then counter-stained with haematoxylin. PBS
alone without primary antibody was used as negative controls
of immunostaining.
Two independent investigators evaluated the immunohistochem-
ical staining without knowledge of the clinico-pathological features
of the tumours. For survivin and COX-2, staining in the nucleus
and cytoplasm was evaluated by scanning of the whole section
and counting more than 1000 representative cells. A semi-quantita-
tive scoring system was used: 0=55% of cells with expression;
1=5–25%; 2=25–50%; 3=50–75%; and 4=475% expression.
Cases with weighted scores 51 were deﬁned as negative, and were
otherwise deﬁned as positive.
Western blot
Protein was extracted as described previously (Leung et al, 2000a).
Gastric tissues and cell lines were homogenized in Tris-HCl
(pH 7.4) buffer containing 0.5% Triton X-100 and protease inhibi-
tor cocktail (Roche, Indiapolis, IN, USA). Protein concentrations
were measured by the method of Bradford (Bio-Rad). Sixty micro-
grams of protein was loaded per lane, separated by 10% SDS-
polyacrylamide gel electrophoresis under reducing conditions,
and transferred onto equilibrated polyvinylidene diﬂuoride
membrane (Amersham) by electroblotting. Membranes were
blocked by 5% non-fat dry milk and then incubated with an anti-
body against survivin (dilution 1:1000) and COX-2 respectively
for 3 h. After secondary antibody incubation, survivin and COX-
2 was detected by enhanced chemiluminescence method (Pierce,
Rockford, IL, USA) (Figure 3).
In situ DNA nick end labelling (TUNEL)
Apoptosis was determined by the terminal deoxynucleotidyl trans-
ferase (TdT)-mediated deoxyuridine triphosphate nick-end
labelling (TUNEL) technique (ApopTag; Intergen, Purchase, NY,
USA) as described previously (Leung et al, 2000b). Nuclei with
clear brown staining were regarded as positive (Figure 2B). The
apoptosis index was calculated as the percentage of TUNEL-posi-
tive nuclei after counting more than 1000 epithelial cells.
Statistical analysis
Statistical analysis was performed using the Statistical Package for
the Social Science program (SPSS, version 9.0). The correlation
between survivin expressions and various clinicopathological
features of tumours was analysed by using either the w
2 test or
Student’s t-test. The association between survivin and COX-2 was
analysed by Spearman’s rank correlation analysis. Differences in
apoptosis index were analysed by the independent Wilcoxon test.
A two-side P value of less than 0.05 was considered statistically
signiﬁcant.
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Figure 3 (A) Representative samples of Western blotting for survivin
and COX-2 proteins in human gastric cancer cell lines (KatoIII, AGS and
MKN45), gastric cancer tissues (T), paired non-tumour tissues (NT) and
control gastric mucosa (N). The upper panel represents the b-actin levels
as the internal control. (B) Densitometry of survivin and COX-2 proteins,
standardised to b-actin, for the conditions listed above in (A).
Figure 2 (A) Staining of survivin was mainly restricted to tumour cells
(short arrow) but was rarely in the adjacent normal mucosa in this sample
(long arrow, 6250). (B) Apoptotic nuclei as revealed by TUNEL in survi-
vin-positive tumour (long arrow, B1) and in survivin-negative tumour (long
arrow, B2, 6250).
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Expression of survivin mRNA in gastric cancer and in
cancer cell lines
Survivin mRNA expression was undetectable in the normal gastric
mucosa by RT–PCR. By contrast, all ﬁve cancer cell lines, exhibited
survivin expression. Among the 50 gastric cancer samples, survivin
mRNA was detected in 34 (68%) cases whereas 11 (22%) of the adja-
cent non-tumour samples demonstrated survivin expression
(P50.001). Survivin mRNA was, however, not detected in the neigh-
bouring normal tissues when the corresponding cancer tissues were
negative (Figure 1, Table 1). There was no association between survi-
vin expression and clinical-pathological parameters of the gastric
cancers including patients’ demographic data, tumour staging,
presence of lymph node metastasis and tumour subtypes (Table 2).
Survivin protein expression in gastric cancer and
cancer cell lines
Survivin protein expression was studied by Western blot and
immunohistochemistry in 24 randomly selected gastric cancers
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Table 1 Cancer patients characteristics, clinical and molecular ﬁndings
Survivin COX-2
Histology
mRNA Protein* mRNA Protein
Patient Age Sex Lauren type T NT T NT T NT T NT
1 36 F diff + 7 + 7
2 79 M int + 7 ++
3 79 M int 77 77
4 63 M int + 7 + 7
5 79 F int + + + +
6 61 M int + 7 + 7
7 60 M int 77 77
8 62 M diff + 7 + 7
9 52 M int 7700++40
10 72 F diff + 7 ++
11 79 F int 77 ++
12 69 M int 77 ++
13 51 M int + 7 ++
14 45 M diff 77 77
15 69 M diff 77 ++
16 64 F diff 77 ++
17 76 F diff 7700++44
18 63 M int + 7 ++
19 57 M int + 7 ++
20 50 M diff + 7 + 7
21 43 M int + 7 ++
22 74 F diff + 7 ++
23 76 M diff 77007700
24 64 M mix + 77 7
25 73 F diff + + 2 1 + 7 20
26 50 M diff 77007711
27 64 M diff + + + +
28 72 F int + + 0 0 7701
29 59 F int 77107710
30 77 M int + 7 40+7 30
31 65 M int 77007700
32 43 M diff + + 2 0 7700
33 62 M mix + + 3 1 + 7 42
34 80 F int + 7 40++10
35 69 M int 77 ++
36 50 M diff + 7 43+7 42
37 51 M mix + 7 33++20
38 77 M int + + 4 0 + + 4 2
39 60 F diff + + + +
40 70 M int 77007700
41 54 M int + 7 00+7 40
42 83 F int 7720+7 41
43 72 M int + 7 41++21
44 70 F int + 7 407720
45 70 F int + 77 7
46 52 M diff + 7 44+7 41
47 74 F diff + + + +
48 58 M int + + 4 0 + 7 40
49 77 M int + 7 21++10
50 75 F int + + 4 0 + 7 40
T=tumour; NT=adjacent non-tumour; +=positive; 7=negative; int=intestinal; diff=diffuse. *Score of protein expression by immuno-
staining as described in Materials and Methods.
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the gastric mucosa of 20 non-cancer individuals. In keeping with
the ﬁndings by RT–PCR, there was no positive staining in the
normal gastric mucosa tissues from non-cancer patients. In
contrast, survivin was strongly expressed in gastric cancer tissues
(Figure 2). Staining for survivin was observed primarily in the
nuclei but was also weakly present in the cytoplasm. Fifteen out
of 24 cases (62.5%) of gastric cancers were positive while three
(12.5%) of the adjacent non-cancer mucosa exhibited survivin
protein (P=0.001) (Figure 2A). Expression of survivin in gastric
cancer and cancer cell lines was further conﬁrmed by immunoblot
which revealed a 16.5 kDa band protein (Figure 3). Strong expres-
sion of survivin protein was demonstrated in 14 of the 24
(58.3%) gastric cancer tissues and in all ﬁve gastric cancer cell
lines. Weak expression was detected in the adjacent normal muco-
sa whereas survivin protein was undetectable in normal controls.
The presence of the respective mRNA moiety was more frequent
than the respective protein, due to the diverse sensitivity of the
methods used for analysis. However, for survivin a consistent
correlation between the survivin protein and mRNA levels was
observed.
Survivin expression in ﬁrst-degree relatives
A total of 30 ﬁrst-degree relatives were examined for survivin
mRNA expression in the gastric corpus and antrum. Increased
survivin expression was seen in seven corpus biopsies (23%) and
in ﬁve antral biopsies (17%) (Table 3). When compared to normal
gastric tissues from the 20 control subjects, survivin expression was
more frequently detected in both the corpus (P=0.02) and the
antrum (P=0.046) of ﬁrst-degree relatives. Among the 60 speci-
mens obtained from the corpus and antrum of ﬁrst-degree
relatives, six were classiﬁed as severe gastritis, 18 as moderate
gastritis, 21 as mild gastritis and 15 as normal. Survivin expression
was more often increased in gastric biopsies with moderate and
severe gastritis (9/24, 37.5%) than in samples with mild or no
gastritis (3/36, 8.3%; P=0.009). In keeping with the ﬁndings by
RT–PCR, staining for survivin was observed in gastric epithelial
cells in two out of 10 ﬁrst degree relatives.
Survivin expression and H. pylori infection
First-degree relatives and control subjects with proper diagnosis of
H. pylori infection were studied for the relationship between survi-
vin mRNA expression and H. pylori infection. In total, 88 gastric
tissue samples from relatives and normal control subjects were
analysed. Eight of 30 (26.7%) specimens with H. pylori infection
showed increased survivin expression, whereas three out of 58
(5.2%) specimens without H. pylori infection had survivin expres-
sion (P=0.006).
Correlation between survivin expression and apoptosis
The relationship between survivin expression and apoptosis index
of gastric tumours was studied. In gastric tumours with survivin
expression, the mean apoptosis index was 1.07% (SD=0.54), which
was signiﬁcantly lower than survivin-negative tumours (1.80%,
SD=1.62; P=0.02) (Figure 2B).
Correlation between survivin and COX-2 expression
As shown in Table 1, increased COX-2 mRNA expression was
detected in 37 of 50 (74%) gastric cancer and 23 (46%) adjacent
non-tumour tissues. By immunohistochemistry, COX-2 protein
expression was found in 15 of 24 (62.5%) cancers and four
(16.7%) adjacent normal specimens. The correlation between survi-
vin and COX-2 expression was evaluated in the same tissue
specimens of each individual patient by RT–PCR and by immuno-
histochemistry. There was a signiﬁcant correlation at per case level
between survivin and COX-2 mRNA expression in gastric tumour
samples (r=0.523; P=0.001). In agreement with mRNA expression,
a similar correlation was demonstrated by parallel immunostaining
of gastric cancer specimens (r=0.420, P=0.041). However, a similar
correlation could not be demonstrated in adjacent non-tumour
tissues and in gastric biopsies obtained from ﬁrst-degree relatives.
DISCUSSION
Development of gastric cancer, like many other malignancies, is a
multi-step process involving the accumulation of mutations and
changes in cell cycle regulatory mechanisms. The detection of these
alterations in the early stage of cancer development may shed new
light into the gastric carcinogenesis process. Our previous studies
showed that these changes are not merely found in gastric cancer
cells but also in adjacent non-tumour tissues as well as in ﬁrst-
degree family members of cancer patients (Ebert et al, 2000; Yu
et al, 2000a,b). In this study, survivin mRNA expression was
detected in the majority of gastric cancers and in all cancer cell
lines. In this regard, two recent studies showed that 35–82% of
gastric cancers express survivin protein by using immunohisto-
chemistry (Lu et al, 1998; Okata et al, 2001). In contrast to
previous studies, we also examined survivin expression at the
RNA and protein levels. In this study, we demonstrated that survi-
vin was not detected in the gastric mucosa from normal control
subjects whereas the adjacent non-tumour gastric mucosa of survi-
vin-positive tumours occasionally expressed survivin. This ﬁnding
is in keeping with those found in colorectal and oesophageal cancer
where survivin expression was demonstrated in adjacent normal
tissues (Sarela et al, 2000; Kato et al, 2001).
Past epidemiological studies revealed that ﬁrst-degree relatives
have an approximately three-fold increase in risk of developing
gastric carcinoma, suggesting the existence of a genetic susceptibil-
ity to cancer (Zanghieri et al, 1990; La Vecchia et al, 1992). In this
study, we observed an increased survivin mRNA expression in the
gastric mucosa of ﬁrst-degree relatives but not in normal control.
Thus, survivin may play an important role in the early stage of
development of gastric cancer within family members. One of
the plausible explanations for these ﬁndings may be related to H.
pylori infection. H. pylori infection is considered to be an impor-
tant triggering factor for gastric carcinogenesis (Correa, 1992).
Notably, our present study demonstrates that survivin expression
correlates with the severity of gastritis and H. pylori infection in
non-cancer patients. On the other hand, this appears to contradict
with the observation that chronic gastritis and H. pylori infection is
associated with increased epithelial cell apoptosis (Attallah et al,
1996; Moss et al, 1996; Wagner et al, 1997; Leung et al, 2000b).
We speculated that the increased survivin expression in these
tissues may be secondary to the pro-apoptotic stimuli induced by
H. pylori. Up-regulation of survivin, an anti-apoptosis protein, then
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Table 2 Association between tumour expression of survivin mRNA and
clinicopathological characteristic of patients with gastric cancer
Survivin
Variable Category Total no positive no (%) P value
Sex Male 33 22 (66.7) 40.05
Female 17 12 (70.6)
Age 4=60 y 35 23 (65.7) 40.05
560 y 15 11 (73.3)
Lymph node metastasis*
Present 33 21 (63.6) 40.05
Absent 14 9 (64.3)
Lauren classiﬁcation
Intestinal type 29 19 (65.5) 40.05
Diffuse type 18 12 (67.9)
*Data missed in three cases.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(1), 91–97offers an advantage to a rapidly growing tumour by slowing down
the cell loss rate and ultimately leading to neoplastic transforma-
tion. This study may offer a further possible biological link
between chronic H. pylori infection and gastric cancer develop-
ment.
In this study, gastric cancers with survivin expression had a
reduced apoptosis index, which is in keeping with the previous
report by Lu et al (1998). Additionally, these investigators demon-
strated an association between survivin and p53 and bcl-2
expression in gastric cancers. While p53 and bcl-2 are involved in
the modulation of cell progression and viability, the role of other
mediators of apoptosis has not been examined yet. Previously,
we have demonstrated COX-2 up-regulation in gastric cancer
and pre-neoplastic gastric lesions that may play contribute to the
carcinogenesis process (Sung et al, 2000; Leung et al, 2001). Over-
expression of COX-2 in intestinal epithelial cells results in
inhibition of apoptosis (Tsujii and DuBois, 1995), which is similar
to the action of survivin. A key question we have addressed here is
whether there is any correlation between COX-2 and survivin
expression in gastric tumour. Our results show a strong association
between survivin and COX2 expression in gastric cancer. The co-
expression of survivin and COX-2 demonstrated in this study is
intriguing. Survivin blocks apoptosis by targeting the terminal
effector caspase-3 and caspase-7 (Adida et al, 1998; Tamm et al,
1998) whereas stimulation of ceramide may be one of the molecu-
lar basis for the anti-apoptotic effect of COX-2 (Chan et al, 1998).
Whether there is any link between these intermediate pathways
may require further studies. Alternatively, common transcriptional
factors may be involved in the co-regulation of survivin and COX-
2 gene in gastric cancer.
In summary, we have demonstrated the up-regulation of survi-
vin in gastric cancer and the adjacent non-tumour area as well as
in a proportion of ﬁrst-degree cancer relatives. Expression of survi-
vin in gastric cancer was associated with reduced apoptosis and
COX-2 expression. On the other hand, expression of survivin in
non-neoplastic tissues is closely associated with H. pylori infection
and gastric inﬂammation. Collectively, these ﬁndings indicate that
inhibition of apoptosis regulated by survivin is important in the
pathogenesis of gastric cancer.
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Table 3 Parameters of histological ﬁndings and mRNA expression in ﬁrst degree relatives
Antrum Corpus
Gastri-
tis mRNA
Gastri-
tis mRNA
No Age Sex G A IM HP Survivin COX-2 G A IM Hp Survivin COX-2
12 7 M 3 3 7 ++ 7 227 + 7 +
25 7 M 3 1 + 77 7 42+ + 77
32 8 F 1 1 77 7 7 1177 + 7
43 7 M 3 2 + + + 7 337 ++ +
56 4 M 3 3 7 + 77 337 + 7 +
65 4 F 4 3 + + + +3 3 7 ++ 7
76 7 F 2 1 77 7 7 33+ + + 7
83 3 F 3 3 7 ++ + 2 2 7 + 77
92 6 F 3 3 7 + 77 227 + 77
10 42 F 2 1 77 7 +4 3 77 + 7
11 74 F 4 3 + + 7 +3 3 7 ++ 7
12 70 F 2 1 77 7 7 2177 7 7
13 41 F 2 1 77 7 7 2177 + 7
14 43 F 3 3 7 + 77 337 + 77
15 53 F 4 3 + + 77 227 + 77
16 64 F 1 1 77 7 7 1177 7 7
17 37 F 4 3 7 + 77 327 + 77
18 53 M 3 2 77 7 7 2177 7 7
19 60 F 3 2 7 + 7 +2 2 7 + 77 l
20 55 F 2 1 77 7 7 2177 7 7
21 37 F 3 2 7 + 7 +3 3 7 + 77
22 24 F 2 1 77 7 7 1177 7 7
23 49 M 2 1 77 7 7 2177 7 7
24 63 M 2 1 77 7 7 2177 7 7
25 52 M 1 1 77 7 7 1177 7 7
26 41 F 1 1 77 7 7 1177 7 7
27 24 F 2 1 7 nd + 7 227 nd 77
28 62 M 1 1 77 7 7 1177 7 7
29 50 F 1 1 77 7 7 1177 7 7
30 72 F 1 1 + 77 7 11+77 7
+=Positive; 7=negative; IM=interstitial metaplasia; Hp=Helicobacter pylori; nd=not determined; 1=no gastritis/activity; 2=mild gastritis/
activity; 3=moderate gastritis/activity; 4=severe gastritis/activity.
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